Hexavalent vaccine surveillance
Executive Summary
Aventis and GlaxoSmithKline's hexavalent vaccines under surveillance by European regulatory authorities following report of four deaths in two-year-olds within 48 hours of vaccination with Aventis' Hexavac. Hexavalent vaccines are not licensed in the U.S.; Aventis has said it will file Hexavac with FDA in 2005-2006...
You may also be interested in...
Sanofi Pasteur/Merck Expect Hexavac Market Return Following Suspension
Merck is working with European regulatory authorities to address immunogenicity concerns involving the hepatitis B component of its Hexavac pediatric vaccine
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.